The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.
 
Crescens Diane Tiu
No Relationships to Disclose
 
Sarah Derby
No Relationships to Disclose
 
Noor Md Haris
No Relationships to Disclose
 
Liam Welsh
No Relationships to Disclose
 
Anna Stansfeld
No Relationships to Disclose
 
Thomas Hundsberger
Consulting or Advisory Role - Bayer; Novocure (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Patrick Roth
Honoraria - Merck; Novocure; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Debiopharm Group; MSD; QED Therapeutics; Virometix
Research Funding - MSD (Inst); Novocure (Inst)
 
Fatima König
No Relationships to Disclose
 
Joel Robert Eisner
Employment - GeneCentric; Innocrin Pharma
Stock and Other Ownership Interests - GeneCentric; Innocrin Pharma
Consulting or Advisory Role - Propella Therapeutics
Patents, Royalties, Other Intellectual Property - Provisional patents for GeneCentric and Innocrin Pharma as part of my employments
 
Malte Kleinschmidt
Employment - Targos GmbH
Leadership - Targos GmbH
 
Stephanie Anderson
Employment - Basilea
Stock and Other Ownership Interests - Basilea
Travel, Accommodations, Expenses - Basilea
 
Felix Bachmann
Employment - Basilea Pharmaceutical
Stock and Other Ownership Interests - Basilea Pharmaceutical; Clinuvel
Patents, Royalties, Other Intellectual Property - Basilea Pharmaceutical (Inst)
 
Heidi A Lane
Employment - Basilea Pharmaceutical; Novartis (I)
Stock and Other Ownership Interests - Basilea Pharmaceutical; Clinuvel; Eiger BioPharmaceuticals; Fresenius; Lilly; Merck; Roche
Patents, Royalties, Other Intellectual Property - Basilea Pharmaceutical (Inst)
 
Marc Engelhardt
Employment - Basilea
 
Thomas Kaindl
Employment - Basilea
 
Karine Litherland
Employment - Basilea
 
Alexandru C Stan
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Basilea; Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech